Teva Pharmaceuticals
TEVA
Market cap $17.8B

15.51 USD

-0.07

0.45%

At close Apr 30, 4:00 PM EDT

After hours

15.64

+0.13

0.84%

1 day

-0.45%

5 days

8.16%

1 month

0.91%

3 months

-13.06%

6 months

-16.57%

Year to date

-27.18%

1 year

10.39%

5 years

44.41%

10 years

-74.33%

About: Teva Pharmaceutical Industries, based in Israel, is the leading generic drug manufacturer in the world. Teva derives half of its sales from North America and makes up a high-single-digit percentage of the total number of generic prescriptions in the US. It also has a significant presence in Europe, Japan, Russia, and Israel. Besides generics, Teva has a portfolio of innovative medicines and biosimilars in three main therapeutic areas: the central nervous system with Copaxone, Ajovy, and Austedo; respiratory with Qvar and ProAir; and oncology with Truxima, Herzuma, and Bendeka/Treanda. Teva also sells active pharmaceutical ingredients, offers contract manufacturing services, and owns Anda, a US-based generic and specialty drug distributor.

Employees: 35,686

Healthcare Drug Manufacturers - Specialty & Generic

0

Funds holding %

of 7,425 funds

–

Analysts bullish %

Fund manager confidence

Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)

109% more first-time investments, than exits

New positions opened: 94 | Existing positions closed: 45

81% more call options, than puts

Call options by funds: $727M | Put options by funds: $402M

31% more capital invested

Capital invested by funds: $11.2B [Q3] → $14.7B (+$3.43B) [Q4]

29% more funds holding in top 10

Funds holding in top 10: 28 [Q3] → 36 (+8) [Q4]

7% more funds holding

Funds holding: 533 [Q3] → 568 (+35) [Q4]

2.7% more ownership

Funds ownership: 55.99% [Q3] → 58.69% (+2.7%) [Q4]

2% more repeat investments, than reductions

Existing positions increased: 191 | Existing positions reduced: 187

See Fund Rankings

Research analyst outlook

1 Wall Street Analyst provided 1 year price targets over the past 3 months

Low target

$20

29%

upside

Avg. target

$20

29%

upside

High target

$20

29%

upside

1 analyst rating

1 positive

100%

0 neutral

0%

0 negative

0%

B of A Securities

Jason Gerberry

26% 1-year accuracy

5 / 19 met price target

29%upside

$20

Buy

Maintained

6 Mar 2025

See Analyst Rankings

Financial journalist opinion

Based on 7 articles about TEVA published over the past 30 days

The Motley Fool

Trump Tariff Sell-Off: 3 Superb Stocks That Make for No-Brainer Buys Right Now

When examined over long stretches, stocks stand atop the pedestal in terms of annualized return, relative to all other asset classes. But this doesn't mean the Dow Jones Industrial Average (^DJI -1.33%), S&P 500 (^GSPC 0.13%), and Nasdaq Composite (^IXIC -0.13%) move from Point A to B in a straight line.

Trump Tariff Sell-Off: 3 Superb Stocks That Make for No-Brainer Buys Right Now

24/7 Wall Street

Billionaire Sold Broadcom And Bought This Stock That Could Soar 121%

TEVA has 121% upside from its share price today. Retiring early is possible, and may be easier than you think.

Billionaire Sold Broadcom And Bought This Stock That Could Soar 121%

The Motley Fool

5 of the Safest Stocks Billionaire Money Managers Bought Ahead of Wall Street's Historic Volatility

For more than a century, the stock market has been the premier wealth creator for investors. But this doesn't mean stocks move higher in a straight line.

5 of the Safest Stocks Billionaire Money Managers Bought Ahead of Wall Street's Historic Volatility

CNBC Television

BMO's Siegerman talks the impact of tariffs on pharmaceutical stocks

Evan Seigerman, BMO, joins 'Fast Money' to talk the impact of tariffs on pharma space.

BMO's Siegerman talks the impact of tariffs on pharmaceutical stocks

Trump's Tariffs Circle Pharma Industry: Who It Affects And How It May Play Out

The Trump administration's proposed tariffs on pharmaceuticals have caused significant market turmoil today, with major Pharma stocks plummeting globally. Despite pledges to increase U.S. manufacturing, companies like Eli Lilly and Novo Nordisk are suffering substantial share price declines. The feasibility of relocating drug manufacturing to the U.S. is highly questionable, potentially leading to drug shortages and higher domestic prices.

Trump's Tariffs Circle Pharma Industry: Who It Affects And How It May Play Out

Investors Business Daily

Dow Jones, S&P 500 Pharma Names Slammed As New Trump Tariffs Target Drug Imports

Big pharmaceutical names plowed lower Wednesday after Trump on Tuesday said that tariffs would take direct aim at drug imports. The post Dow Jones, S&P 500 Pharma Names Slammed As New Trump Tariffs Target Drug Imports appeared first on Investor's Business Daily.

Dow Jones, S&P 500 Pharma Names Slammed As New Trump Tariffs Target Drug Imports

Teva Announces FDA Filing Acceptance for AJOVY® (fremanezumab) in Pediatric Episodic Migraine Prevention

PARSIPPANY, N.J. and TEL AVIV, April 07, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), announced today that the U.S. Food and Drug Administration (FDA) has accepted its supplemental Biologics License Application (sBLA) for AJOVY® (fremanezumab-vfrm) to expand the indication to include the prevention of episodic migraine in children and adolescent patients aged 6-17 years who weigh 45 kilograms (99 pounds) or more. If approved, AJOVY would be the only calcitonin gene-related peptide (CGRP) antagonist for migraine prevention in adults and episodic migraine prevention in pediatric patients, helping to address the high unmet need for effective treatments for those living with migraine.

Teva Announces FDA Filing Acceptance for AJOVY® (fremanezumab) in Pediatric Episodic Migraine Prevention

New Data Strengthens Teva's Schizophrenia Portfolio, Including Phase 3 SOLARIS Trial Survey Results Demonstrating Patient and Healthcare Professional Satisfaction with TEV-'749 (olanzapine) as a Once-Monthly Subcutaneous Long-Acting Injectable

PARSIPPANY, N.J. and TEL AVIV, Israel, March 31, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced the presentation of a patient and healthcare professional (HCP) attitudes and experiences survey study, complementing the successful Phase 3 Subcutaneous Olanzapine Extended-Release Injection Study (SOLARIS) evaluating TEV-'749. More than 92% of patients, 87% of nurses and 72% of physicians were either satisfied or very satisfied when asked about TEV-'749, overall, including initiation regimen, monthly dosing schedule and dosing options.1 The data were presented at the 2025 Congress of the Schizophrenia International Research Society (SIRS) taking place from March 29 to April 2, 2025, in Chicago, IL.

New Data Strengthens Teva's Schizophrenia Portfolio, Including Phase 3 SOLARIS Trial Survey Results Demonstrating Patient and Healthcare Professional Satisfaction with TEV-'749 (olanzapine) as a Once-Monthly Subcutaneous Long-Acting Injectable

The Motley Fool

These Are My 3 Worst-Performing Stocks So Far in 2025 -- and the One I'm Buying More of Now

It's hard to believe, but the first quarter of 2025 is rapidly coming to a close. After doing a quick portfolio checkup, I found that I have stocks that have gained as much as 40% already this year, but I also have a few that are down nearly 30%.

These Are My 3 Worst-Performing Stocks So Far in 2025 -- and the One I'm Buying More of Now

Teva Releases Q1 2025 Aide Memoire

TEL AVIV, Israel, March 27, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that its Q1 2025 Aide Memoire is available on the “Investors” page on its website.

Teva Releases Q1 2025 Aide Memoire

See News Rankings

Charts implemented using Lightweight Charts™